Market Place
Sourcing Support
Theriva Reaches VIRAGE Trial Enrollment For Pancreatic Cancer
23 Sep 2024 //
GLOBENEWSWIRE
Immuneering Reports Positive Phase 2a Data For IMM-1-104
12 Sep 2024 //
GLOBENEWSWIRE
RenovoRx Enrolls First Patient In Phase III TIGeR-PaC Trial At Nebraska Medical
14 Aug 2024 //
GLOBENEWSWIRE
FibroGen Reports Pamrevlumab Pancreatic Cancer Study Results
30 Jul 2024 //
GLOBENEWSWIRE
RenovoRx Announces Publication Acceptance In The Oncologist
08 Jul 2024 //
GLOBENEWSWIRE
Precision-Panc Team Opens PRIMUS-006 Study For Gemcitabine, Pembrolizumab
18 Jun 2024 //
GLOBENEWSWIRE
BMS`s Opdivo Combo Approved In EU For 1L Urothelial Carcinoma
29 May 2024 //
BUSINESSWIRE
US FDA grants fast track designation to Theriva Biologics’ VCN-01
27 May 2024 //
PHARMABIZ
Verastem Pancreatic Interim Positive: Avutometinib Defactinib Chemo Combo
23 May 2024 //
BUSINESSWIRE
Zentalis Azenosertib Gemcitabine: Osteosarcoma Phase 1 At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib
16 May 2024 //
PHARMABIZ
CHMP Adopts Positive Opinion for Opdivo® in 1L Urothelial Cancer
26 Apr 2024 //
BUSINESSWIRE
FDA Approves Opdivo for First-Line Treatment of Urothelial Carcinoma
07 Mar 2024 //
BUSINESSWIRE
Polaris Initiates Ph 3 Trial: First Patient Dosed with ADI-PEG 20/Placebo
04 Dec 2023 //
GLOBENEWSWIRE
Merck Receives Positive EU CHMP Opinion for KEYTRUDA for Biliary Tract Cancer
10 Nov 2023 //
BUSINESSWIRE
FDA Approves Merck’s KEYTRUDA & Cisplatin as Treatment for Biliary Tract Cancer
01 Nov 2023 //
BUSINESSWIRE
Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer
30 Jun 2023 //
ONCLIVE
Preliminary Result with CYT-0851 in Advanced Solid Tumors Show Clinical Activity
03 Jun 2023 //
BUSINESSWIRE
Panbela Announces First Patient Enrolled in ASPIRE Trial Studying Ivospemin
07 Mar 2023 //
GLOBENEWSWIRE
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy
18 Jan 2023 //
BUSINESSWIRE
Theriva Announces First Patient Dosed in Phase 2b VIRAGE Trial of VCN-01
18 Jan 2023 //
GLOBENEWSWIRE
Tiziana Life Announces IND filed for Phase 2 of Milciclib with Gemcitabine
04 Jan 2023 //
GLOBENEWSWIRE
Panbela Receives EMA Opinion on Orphan Designation for Ivospemin
14 Dec 2022 //
GLOBENEWSWIRE
Panbela Receives Approvals to Open Sites in Spain, France & Italy for SBP-101
30 Sep 2022 //
GLOBENEWSWIRE
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101
11 Aug 2022 //
GLOBENEWSWIRE
NuCana`s twist on chemo drug Gemzar fails in phase 3 again
09 Mar 2022 //
FIERCEPHARMA
Enforcement Report - Week of February 2, 2022
02 Feb 2022 //
FDA
Microcap cancer player goes belly up after pancreatic tumor drug flops key study
27 Jan 2022 //
ENDPTS
Panbela Initiates ASPIRE Study of SBP-101 with Nab-Paclitaxel & Gemcitabine
26 Jan 2022 //
GLOBENEWSWIRE
Panbela Presents Clinical Data on Phase 1b Trial of SBP-101 in Metastatic PDA
24 Jan 2022 //
GLOBENEWSWIRE
Panavance Provides Update on Status of GP-2250 Trial in Pancreatic Cancer
19 Jan 2022 //
BUSINESSWIRE
Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer
18 Jan 2022 //
GLOBENEWSWIRE
Repare Doses First Patient in Phase 1 Clinical Trial of RP-6306 + Gemcitabine
21 Dec 2021 //
BUSINESSWIRE
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing
01 Nov 2021 //
GLOBENEWSWIRE
Erytech`s eryaspase flunks late-stage pancreatic cancer trial; shares drop
26 Oct 2021 //
MARKETWATCH
Bristol Myers` Abraxane falls into shortage from manufacturing woes
20 Oct 2021 //
ENDPTS
Rafael Pharmaceuticals Initiates PII for CPI-613+Gemcitabine+Cisplatin in BTC
25 Aug 2021 //
GLOBENEWSWIRE
Merck to discontinue PII study of bintrafusp alfa+gemcitabine+cisplatin for BTC
25 Aug 2021 //
PHARMABIZ
Hikma Intl Pharms`s Generic Gemcitabine Hydrochloride Receives FDA Approval
25 Jun 2021 //
FDA
Patent Expiry of Branded Oncology Products in Gemcitabine HCL Market
23 Jun 2021 //
PRNEWSWIRE
Pamrevlumab Included in PCAN’s Adaptive Clinical Trial Platform
16 Jun 2021 //
GLOBENEWSWIRE
AB Science announces results from masitinib study AB12005 presented at 2021 ASCO
10 Jun 2021 //
PRESS RELEASE
NKMax, Merck expand clinical collaboration to include phase I/IIa trial of SNK01
14 Apr 2021 //
PHARMABIZ
Nanjing King`s Generic Gemcitabine Hydrochloride Receives Approval in US
15 Dec 2020 //
FDA
Innovent & Lilly At ESMO Presents Ph Iii Results Of Tyvyt® + Alimta®
20 Sep 2020 //
PRNEWSWIRE
RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer
03 Jun 2020 //
PRNEWSWIRE
Tyvyt® Combined with Gemzar® and Platinum Chemotherapy Met Predefined Endpoint
06 May 2020 //
PRNEWSWIRE
Ascentage Pharma Announces Approval for the Ph Ib/II Clinical Trial of APG-1387
24 Feb 2020 //
PR NEWSWIRE
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab
27 Jan 2020 //
BUSINESSWIRE
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
20 Jan 2020 //
PR NEWS WIRE
BridgeBio Pharma`s QED Therapeutics Receives Fast Track Designation
06 Jan 2020 //
GLOBE NEWSWIRE
After Cancer Drug Fails Pancreatic Cancer Trial, Lilly Plans to Continue Studies
17 Oct 2019 //
BIOSPACE
Lilly`s Armo buyout drug a bust in pancreatic cancer
17 Oct 2019 //
FIERCE BIOTECH
Shilpa Medicare`s Generic Gemcitabine Hydrochloride Receives Approval in US
09 Oct 2019 //
FDA
Roche`s Tecentriq excels in another lung cancer study
13 Sep 2019 //
ENDPOINTSNEWS
NuCana`s retooled chemo drug comes up short in pancreatic cancer
22 Aug 2019 //
FIERCE BIOTECH
Another effort on pancreatic cancer flops, as Boston Biomedical cans Ph 3 test
02 Jul 2019 //
FIERCE BIOTECH
Sun Pharma launches INFUGEM in the U.S.
08 Apr 2019 //
BIOSPECTRUMASIA
Ingenus Pharms`s Generic Gemcitabine Hydrochloride Receives Approval in US
14 Feb 2019 //
FDA
